Foley Hoag Provides IP Due Diligence Counsel to Novartis on Acquisition of Tourmaline Bio
September 09, 2025
Foley Hoag provided IP due diligence counsel to Novartis (NYSE: NVS), a global healthcare company, on its acquisition of Tourmaline Bio, complementing its cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD). The Foley Hoag team was led by Brendan Jones and Erin Foley. Learn more about the transaction here.
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
